Genmab A/S (GMAB) News Today

Genmab A/S (NASDAQ: GMAB) shares have increased amid a wave of positive clinical data, stronger-than-expected financial results and upbeat analyst projections. Investors are focusing on robust trial wins for epcoritamab and other pipeline assets, a solid Q2 earnings beat, raised guidance and favorable consensus targets.

• Positive Sentiment: Wall Street analysts project a 33.8% upside in GMAB based on consensus price targets, reflecting broad agreement on raised earnings estimates. Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
• Positive Sentiment: Genmab’s GEN1286 study suggests new hope for treating advanced solid tumors with its epcoritamab platform. Genmab’s GEN1286 Study: A New Hope for Advanced Solid Tumors
• Positive Sentiment: Shares rose on a Q2 beat—EPS and revenue topped estimates—coupled with a raised full-year outlook and Epkinly trial success. Genmab shares rise on Q2 beat, raised outlook and Epkinly trial success
• Positive Sentiment: Late-stage trial win for the AbbVie-partnered lymphoma therapy epcoritamab bolstered confidence in GMAB’s oncology pipeline. Genmab rises on late-stage trial win for AbbVie-partnered lymphoma therapy
• Positive Sentiment: Q2 2025 earnings call highlighted robust revenue growth and strategic advancements across multiple programs. Genmab AS (GMAB) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements
• Positive Sentiment: Q2 EPS of $0.54 beat by $0.15, with a strong net margin of 35.11% and 18% ROE, underscoring operational efficiency. View Slide Deck
• Positive Sentiment: First-half 2025 revenue rose 19% YoY to $1.64 billion, alongside an sBLA submission for epcoritamab and launch of Tivdak® in Japan. Genmab Announces Financial Results for the First Half of 2025
• Positive Sentiment: Phase 3 EPCORE® FL-1 trial met dual primary endpoints, with a 95.7% ORR and significant progression-free survival benefit in R/R follicular lymphoma. Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints
• Neutral Sentiment: Full Q2 2025 earnings call transcript released, providing detailed management commentary and strategic insights. Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript
• Neutral Sentiment: Company published its Q2 2025 earnings presentation deck, outlining product milestones and updated financial guidance. Genmab A/S 2025 Q2 – Results – Earnings Call Presentation
• Neutral Sentiment: Genmab updated its FY 2025 guidance, forecasting revenue of $3.5 billion–$3.7 billion versus the $3.6 billion consensus.